 | Up a level |
Number of items: 1.
Ng, Kenrick, Metcalf, Rob, Sacco, Joseph, Kong, Anthony, Wheeler, Graham, Forsyth, Sharon, Bhat, Reshma, Ward, Joseph, Ensell, Leah, Lowe, Helen et al (show 5 more authors)
(2023)
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
BMJ open, 13 (11).
e070391-e070391.